(Q34585579)

3 August 2017

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome (English)

1 reference

3 August 2017

myelodysplastic syndrome

1 reference

1

Hagop M Kantarjian

1 reference

3 August 2017

8

Jorge Cortes

1 reference

3 August 2017

2

Susan O'Brien

1 reference

3 August 2017

6

Elias Jabbour

1 reference

3 August 2017

7

Farhad Ravandi

1 reference

PubMed ID

17133405

3 August 2017

Guillermo Garcia-Manero

series ordinal

5

object named as

Guillermo Garcia-Manero

1 reference

3 August 2017

10

Jean-Pierre Issa

1 reference

3 August 2017

3

Jianqin Shan

1 reference

3 August 2017

4

Ahmed Aribi

1 reference

3 August 2017

9

Jan Davisson

1 reference

PubMed ID

17133405

3 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

3 August 2017

1 reference

3 August 2017

109

1 reference

3 August 2017

265-273

1 reference

3 August 2017

2

1 reference

Proposals for the classification of the myelodysplastic syndromes

3 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

Novel therapies for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

Bayesian clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22376

7 January 2021

Identifiers

DOI

10.1002/CNCR.22376

1 reference

3 August 2017

1 reference

PubMed ID

17133405